Khalil Zeyad, Maher Soheir
General Medicine, October 6 University, Cairo, EGY.
Emergency Medicine, Al-Fares Crystal Medical Complex, Makka, SAU.
Cureus. 2024 Jul 6;16(7):e63995. doi: 10.7759/cureus.63995. eCollection 2024 Jul.
Microbiome dysbiosis has emerged as a critical factor influencing the outcomes of hematopoietic stem cell transplantation (HSCT). This comprehensive review delves into the intricate relationship between microbiome composition and HSCT outcomes, highlighting the mechanisms through which dysbiosis impacts engraftment, graft-versus-host disease (GVHD), infection rates, and overall survival. The gut microbiome plays a pivotal role in modulating immune responses and maintaining intestinal homeostasis, both of which are crucial for the success of HSCT. This review aims to elucidate the underlying pathways and potential therapeutic strategies to mitigate adverse outcomes associated with microbiome imbalances in HSCT patients. Integrating microbiome modulation strategies such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and antibiotic stewardship into clinical practice can significantly improve patient outcomes and quality of life post-transplantation.
微生物群失调已成为影响造血干细胞移植（HSCT）结果的关键因素。这篇综述深入探讨了微生物群组成与HSCT结果之间的复杂关系，强调了失调影响植入、移植物抗宿主病（GVHD）、感染率和总生存率的机制。肠道微生物群在调节免疫反应和维持肠道内环境稳定方面起着关键作用，而这两者对于HSCT的成功都至关重要。本综述旨在阐明减轻HSCT患者微生物群失衡相关不良后果的潜在途径和治疗策略。将益生菌、益生元、粪便微生物群移植（FMT）和抗生素管理等微生物群调节策略纳入临床实践，可以显著改善移植后患者的预后和生活质量。
